Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 May;5(5):1448-1452.
doi: 10.3892/ol.2013.1264. Epub 2013 Mar 19.

Chemotherapy for gliomas in mainland China: An overview

Ke Sai  1 , Qun-Ying Yang, Dong Shen, Zhong-Ping Chen
Affiliations

Chemotherapy for gliomas in mainland China: An overview

Ke Sai et al. Oncol Lett. 2013 May.

Abstract

Chemotherapy is currently the standard treatment modality for malignant gliomas. Many patients with gliomas are treated in mainland China every year. The history and development of chemotherapy for glioma, however, are not well documented. In this study, an extensive literature search of Pubmed and major Chinese electronic databases was performed to identify clinical studies. A total of 210 publications were identified, with a total of 10,105 patients. Among these studies, 76.2% were retrospective and 23.8% were prospective. Chemotherapy was found to have been administered by the Department of Neurosurgery in 143 studies (68.1%). Oral or intravenous administration was found in 55.7% of studies, followed by intra-arterial (26.7%) and interstitial (15.7%) chemotherapy. Nitrosoureas were the most frequently used chemotherapeutic agents, as found in 133 studies (63.3%). Since 2003, 56 studies on temozolomide (TMZ) have been published. Studies on chemotherapy for gliomas began in the 1970s in mainland China but well-designed randomized controlled trials (RCTs) are rare. Much effort and collaboration should be made to carry out high-quality multicenter RCTs on chemotherapy for gliomas.

Keywords: chemotherapy; glioma; mainland China.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The number of studies on chemotherapy for gliomas published each year from 1970–2011. *Up to August 2011.
Figure 2
Figure 2
Departments where chemotherapy was administered. Neuro, neurosurgery; RT, radiotherapy; MO, medical oncology.
Figure 3
Figure 3
The number of patients enrolled in studies.
Figure 4
Figure 4
Chemotherapeutic agents used in studies. TMZ, temozolomide.
Figure 5
Figure 5
Trend in the publications of studies on temozolomide (TMZ) in the treatment of gliomas. *Up to August 2011.
Figure 6
Figure 6
Approaches employed to administer chemotherapeutic agents in studies.
Figure 7
Figure 7
Clinical information reported in studies.
See this image and copyright information in PMC

References

    1. Schwartzbaum JA, Fisher JL, Aldape KD, Wrensch M. Epidemiology and molecular pathology of glioma. Nat Clin Pract Neurol. 2006;2:494–503. quiz 1 p following 516. - PubMed
    1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10–29. - PubMed
    1. Minniti G, Muni R, Lanzetta G, Marchetti P, Enrici RM. Chemotherapy for glioblastoma: current treatment and future perspectives for cytotoxic and targeted agents. Anticancer Res. 2009;29:5171–5184. - PubMed
    1. Cairncross G, Macdonald D, Ludwin S, et al. Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials. Group J Clin Oncol. 1994;12:2013–2021. - PubMed
    1. Yung WK, Prados MD, Yaya-Tur R, et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor. Group J Clin Oncol. 1999;17:2762–2771. - PubMed

LinkOut - more resources